iMQT_020

Overview

iMQT_020 is a selective allosteric SLC1A5_var inhibitor. iMQT_020 disrupts the trimeric assembly of SLC1A5_var, causing metabolic crisis in cancer cells and selectively suppressing their growth. iMQT_020 reduces glutamine anaplerosis and oxidative phosphorylation , resulting in a broad disruption of cancer metabolism. iMQT_020 reduces GSH levels and increases cellular ROS and mitochondrial ROS . iMQT_020 induces apoptosis and ferroptosis . iMQT_020 can epigenetically upregulate PD-L1 expression. iMQT_020 can be used for the study of pancreatic cancer , lung cancer , and colon cancer .

Application

Products | Products > Disease Areas > Cancer | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Lung Cancer | Products > Disease Areas > Colorectal Cancer | Products > Disease Areas > Digestive System Cancer | Products > Disease Areas > Pancreatic Cancer | Products > Signaling Pathways > Apoptosis | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Signaling Pathways > NF-κB | Products > Signaling Pathways > Immunology/Inflammation | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > PD-1/PD-L1 | Products > Signaling Pathways > Glutathione Peroxidase | Products > Signaling Pathways > Reactive Oxygen Species (ROS) | Products > Signaling Pathways > Apoptosis | Products > Signaling Pathways > Ferroptosis

Product Information

• Catalog No.: HY-179557
• CAS No.: 2463893-46-9
• Molecular Formula: C14H8ClFN2O3
• Molecular Weight: 306.68
• Purity: 99.45%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: ≥ 2.5 mg/mL (8.15 mM); Clear solution
• Availability: In-stock

Source

Original product source